Tilray

TLRY

Börsenwert 449 Mio. $

Canopy Growth maintains a strategic focus on premium cannabis products and European medical distribution. Tilray Brands has expanded into the craft beverage and wellness markets to diversify its revenue streams.

Crack Open the Good Times: Fans 21+ Can Scan the SweetWater QR Code in or Enter Online for a Shot at a Night Out at Georgia Theatre, The Eastern, Variety Playhouse, or Terminal West Crack Open the Good Times: Fans 21+ Can Scan the SweetWater QR Code in or Enter Online for a Shot at a Night Out at Georgia Theatre, The Eastern, Variety Playhouse, or Terminal West

CANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulatory milestone in Europe: INFARMED, Portugal's National Authority of Medicines and Health Products, has approved the quality control laboratory at Tilray Medical's EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The approval gives Tilray Medical greater command over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for pharmaceutical-grade medical cannabis supply across regulated international markets.

Tilray reported Q1-2027 financial results last week with increasing revenue from its BrewDog operations; Cannabis revenue decreased. The company expects its new beer assets along with its international cannabis operations to continue to drive growth. The company reported a net loss and negative free cash flow.

Tilray reported disappointing fiscal Q1 results, missing revenue estimates despite management highlighting record sales. TLRY's revenue growth was driven solely by the BrewDog acquisition; core cannabis sales declined 13%, and the adjusted bottom line swung to a loss. Cash burn surged to $23.4 million, and share dilution remains severe, with shares outstanding up over 31% year-over-year.

Tilray's cash burn continues to be a big problem for investors. The business has been growing through acquisitions, and while that can boost the top line, it can also lead to significantly higher expenses.

Canopy Growth is refining its focus on medical and adult-use markets while managing its U.S. expansion strategy through Canopy USA. Tilray Brands has diversified its revenue stream significantly through a large craft beer and beverage portfolio alongside its global cannabis operations.

Tilray's financial results have been weak for years. The company operates in an uncertain industry.

Tilray Brands TodayTLRYTilray Brands$3.44 -0.15 (-4.04%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$3.38▼$20.20Price Target$6.38Add to WatchlistWhen investors hear talk of U.S. cannabis reform, they often look at major Canadian operators.

Tilray Brands, Inc. (TLRY) Q1 2027 Earnings Call Transcript